Interruption of Service on Telesat's Anik F2 Satellite

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interruption of Service on Telesat's Anik F2 Satellite

OTTAWA, Oct. 02, 2016 (GLOBE NEWSWIRE) -- This evening at approximately 17:00 EDT Telesat’s Anik F2 satellite experienced a technical anomaly that resulted in loss of satellite services to its customers.  Telesat is now undertaking to return the satellite to normal operations and will work to restore traffic in an orderly manner to minimize the impact to our customer networks.  Telesat is in control of the satellite and all indications are that it is healthy. Although there can be no assurance, we expect it will be returned to service by noon EDT tomorrow (i.e., Monday, October 3, 2016).

Further updates will be provided once additional information is available.

About Telesat ( www.telesat.com ) Telesat is a leading global satellite operator, providing reliable and secure satellite-delivered communications solutions worldwide to broadcast, telecom, corporate and government customers. Headquartered in Ottawa, Canada, with offices and facilities around the world, the company’s state-of-the-art fleet consists of 15 satellites plus the Canadian payload on ViaSat-1 with two new satellites under construction. An additional two prototype satellites are under construction and will be deployed in low earth orbit. Telesat also manages the operations of additional satellites for third parties. Privately held, Telesat’s principal shareholders are Canada’s Public Sector Pension Investment Board and Loral Space & Communications Inc. (NASDAQ: LORL ).

Forward-Looking Statements Safe Harbor

This news release contains statements that are not based on historical fact and are ‘‘forward-looking statements’’ within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this news release, the words “expect” and “undertaking to” or other variations of these words or other similar expressions are intended to identify forward-looking statements and information. Actual results may differ materially from the expectations expressed or implied in the forward-looking statements as a result of known and unknown risks and uncertainties. Detailed information about some of the known risks and uncertainties is included in the “Risk Factors” section of Telesat Canada’s Annual Report on Form 20-F for the fiscal year ended December 31, 2015 filed with the United States Securities and Exchange Commission (SEC) as well as Telesat Canada’s other filings with the SEC, which can be obtained on the SEC’s website at www.sec.gov. Known risks and uncertainties include but are not limited to: risks associated with operating satellites and providing satellite services, including satellite construction or launch delays, launch failures, in-orbit failures or impaired satellite performance, volatility in exchange rates and risks associated with domestic and foreign government regulation. The foregoing list of important factors is not exhaustive. The information contained in this news release reflects Telesat’s beliefs, assumptions, intentions, plans and expectations as of the date of this news release. Except as required by law, Telesat disclaims any obligation or undertaking to update or revise the information herein.

For further information:                                                                                John Flaherty, Telesat +1 613 748-8909 (jflaherty@telesat.com)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading